The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance
Abstract
Praziquantel became available for the treatment of schistosomiasis and other trematode-inflicted diseases in the 1970s. It was revolutionary because it could be administered orally and had very few unwanted side effects. As a result of marked reductions in the price of praziquantel, the rate at which it is used has accelerated greatly in recent years. For the foreseeable future it will be the mainstay of programs designed to control schistosome-induced morbidity, particularly in sub-Saharan Africa where schistosomiasis is heavily endemic. There is currently no evidence to suggest that any schistosomes have developed resistance to praziquantel as a result of its widespread use. Nevertheless, while resistance may not pose an obvious or immediate threat to the usefulness of praziquantel, complacency and a failure to monitor developments may have serious consequences in the longer term since it will be the only drug that is readily available for large-scale treatment of schistosomiasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infectious Diseases of Humans: Dynamics and Control
Anderson, R. M., & May, R. M. (1991) · doi:10.1093/oso/9780198545996.001.0001 · Cited by 6,179
Molyneux, D. H., Hotez, P. J., & Fenwick, A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020336 · Cited by 557
The impact of refugia on the development of thiabendazole resistance in Haemonchus contortus
MARTIN, P., LEJAMBRE, L., & CLAXTON, J. (1981) · International Journal for Parasitology · doi:10.1016/0020-7519(81)90023-0 · Cited by 114
Cited by
The genome of the blood fluke Schistosoma mansoni
Berriman, M., Haas, B. J., LoVerde, P. T., Wilson, R. A., Dillon, G. P., Cerqueira, G. C., Mashiyama, S. T., Al-Lazikani, B., Andrade, L. F., Ashton, P. D., et al. (2009) · Nature · doi:10.1038/nature08160 · Cited by 1,058
Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis
Doenhoff, M. J., Cioli, D., & Utzinger, J. (2008) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328318978f · Cited by 806
Self-citationCurrent Status of Vaccines for Schistosomiasis
McManus, D. P., & Loukas, A. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-07 · Cited by 473
Susceptibility or resistance of praziquantel in human schistosomiasis: a review
Wang, W., Wang, L., & Liang, Y.-S. (2012) · Parasitology Research · doi:10.1007/s00436-012-3151-z · Cited by 384
The contribution of mass drug administration to global health: past, present and future
Webster, J. P., Molyneux, D. H., Hotez, P. J., & Fenwick, A. (2014) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2013.0434 · Cited by 307
Metadata
- Authors
- Doenhoff, M. J., & Pica-Mattoccia, L.
- Venue
- Expert Review of Anti-infective Therapy
- Publisher
- Informa UK Limited
- Published
- 2006-04-01
- Volume
- 4
- Issue
- 2
- Pages
- 199-210
- ISSN
- 1478-7210 (ISSN-L)
- 1744-8336
- OpenAlex
- W1988877850
- Cited by
- 203
- References
- 3
- FWCI
- 6.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance. https://app.cochat.ai/papers/10.1586/14787210.4.2.199
- The paper
- Doenhoff, M. J., & Pica-Mattoccia, L. (2006). Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance. Expert Review of Anti-infective Therapy. https://doi.org/10.1586/14787210.4.2.199
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.